Susceptibility to beta-lactam antibiotics in septicemia isolates from twenty-nine European laboratories. European Study Group on Antibiotic Resistance.
{"title":"Susceptibility to beta-lactam antibiotics in septicemia isolates from twenty-nine European laboratories. European Study Group on Antibiotic Resistance.","authors":"","doi":"10.1007/BF02014238","DOIUrl":null,"url":null,"abstract":"<p><p>In 1984 the European Study Group on Antibiotic Resistance (ESGAR) consecutively collected gram-negative bacilli and staphylococci blood isolates and performed susceptibility testing with 11 antibiotics using the microdilution method. In all 2,578 isolates were collected: 68% gram-negative bacilli and 32% staphylococci. The MICs of ampicillin and cefazoline for the susceptible gram-negative bacilli were 1-8 micrograms/ml; of piperacillin less than or equal to 0.5-4; of Sch 34343, cefotaxime, moxalactam, ceftazidime and aztreonam less than or equal to 0.5-2 micrograms/ml; of cefoxitin, cefuroxime and cefamandole less than or equal to 0.5-8 micrograms/ml. For susceptible staphylococci the MICs of cefazoline and cefuroxime were less than or equal to 0.5-1 micrograms/ml, and of cefoxitin, moxalactam, ceftazidime and cefotaxime, less than or equal to 0.5-32 micrograms/ml. The resistance levels varied between laboratories and countries, being lower in Northern Europe. In clinical protocols on patients with gram-negative septicemia from whom cefazoline-resistant strains were isolated, cefotaxime was the beta-lactam most commonly used (12%). In protocols on patients with staphylococcal septicemia from whom gentamicin-resistant or cefazoline-resistant strains were isolated, the most commonly used beta-lactam was cloxacillin (6%).</p>","PeriodicalId":11958,"journal":{"name":"European Journal of Clinical Microbiology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1987-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02014238","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF02014238","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In 1984 the European Study Group on Antibiotic Resistance (ESGAR) consecutively collected gram-negative bacilli and staphylococci blood isolates and performed susceptibility testing with 11 antibiotics using the microdilution method. In all 2,578 isolates were collected: 68% gram-negative bacilli and 32% staphylococci. The MICs of ampicillin and cefazoline for the susceptible gram-negative bacilli were 1-8 micrograms/ml; of piperacillin less than or equal to 0.5-4; of Sch 34343, cefotaxime, moxalactam, ceftazidime and aztreonam less than or equal to 0.5-2 micrograms/ml; of cefoxitin, cefuroxime and cefamandole less than or equal to 0.5-8 micrograms/ml. For susceptible staphylococci the MICs of cefazoline and cefuroxime were less than or equal to 0.5-1 micrograms/ml, and of cefoxitin, moxalactam, ceftazidime and cefotaxime, less than or equal to 0.5-32 micrograms/ml. The resistance levels varied between laboratories and countries, being lower in Northern Europe. In clinical protocols on patients with gram-negative septicemia from whom cefazoline-resistant strains were isolated, cefotaxime was the beta-lactam most commonly used (12%). In protocols on patients with staphylococcal septicemia from whom gentamicin-resistant or cefazoline-resistant strains were isolated, the most commonly used beta-lactam was cloxacillin (6%).